Skip to main content
SpringerLink
Log in

Expression of caveolin-1 in breast cancer stroma as a potential prognostic biomarker of survival and progression: a meta-analysis

  • original article
  • Published:
Wiener klinische Wochenschrift Aims and scope Submit manuscript

Summary

Background

It has been shown that caveolin-1 plays a potential role as a diagnostic and prognostic biomarker in various cancer types. The aim of the present study was to clarify whether caveolin-1 expressed in the breast cancer stroma could be a prognostic factor for breast cancer patients.

Methods

We searched the PubMed, ScienceDirect and Web of Science databases for published literature investigating associations between stromal caveolin-1 expression and survival outcome in breast cancer patients. With respect to survival outcomes, the pooled hazard ratios (HRs) of caveolin-1 and the 95% confidence intervals (CI) were calculated.

Results

Our meta-analysis identified a total of 10 studies involving 2072 cases. Further investigation demonstrated that a lack of caveolin-1 expression in the breast cancer stroma is a hazard for overall survival (OS) (HR = 2.33, 95% CI: 1.57–3.46) and disease-free/progression-free survival (DFS/PFS) (HR = 3.05, 95% CI: 2.26–4.12) in breast cancer patients. Moreover, lack of caveolin-1 expression in the cancer-associated fibroblasts was a significant predictor of DFS/PFS (HR = 2.79, 95% CI: 1.75–4.46).

Conclusion

Our results indicated that lack of expression of caveolin-1 in the breast cancer stroma is associated with a poor prognosis.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015;136(5):E359–E386.

    Article  CAS  PubMed  Google Scholar 

  2. Cardoso F, Harbeck N, Barrions CH, Bergh J, Cortes J, Saghir EIN, et al. Research needs in breast cancer. Ann Oncol. 2016; doi:10.1093/annonc/mdw571.

    PubMed Central  Google Scholar 

  3. Schetter AJ, Leung SY, Sohn JJ, Zanetti KA, Bowman ED, Yanaihara N, et al. MicroRNA expression profiles associated with prognosis and therapeutic outcome in colon adenocarcinoma. JAMA. 2008;299:425–36.

    CAS  PubMed  PubMed Central  Google Scholar 

  4. Mueller MM, Fusenig NE. Friends or foes-bipolar effects of the tumour stroma in cancer. Nat Rev Cancer. 2004;4:839–49.

    Article  CAS  PubMed  Google Scholar 

  5. Allinen M, Beroukhim R, Cai L, Brennan C, Lahti-Domenici J, Huang H, et al. Molecular characterization of the tumor microenvironment in breast cancer. Cancer Cell. 2004;6:17–32.

    Article  CAS  PubMed  Google Scholar 

  6. Sotgia F, Martinez-Outschoorn UE, Howell A, Pestell RG, Pavlides S, Lisanti MP. Caveolin-1 and cancer metabolism in the tumor microenvironment: markers, models, and mechanisms. Annu Rev Pathol. 2012;7:423–67.

    Article  CAS  PubMed  Google Scholar 

  7. Martinez-Outschoorn U, Sotdia F, Lisanti MP. Tumor microenvironment and metabolic synergy in breast cancers: critical importance of mitochondrial fuels and function. Semin Oncol. 2014;41:195–216.

    Article  CAS  PubMed  Google Scholar 

  8. Pucci M, Bravata V, Forte GI, Cammarata FP, Messa C, Gilardi MC, Minafra L. Caveolin-1, breast cancer and ionizing radiation. Cancer Genomics Proteomics. 2015;12:143–52.

    CAS  PubMed  Google Scholar 

  9. Witkiewicz AK, Dasgupta A, Sammons S, Er O, Potoczek MB, Guiles F, et al. Loss of stromal caveolin-1 expression predicts poor clinical outcome in triple negative and basal-like breast cancers. Cancer Biol Ther. 2010;10:135–43.

    Article  PubMed  PubMed Central  Google Scholar 

  10. Simpkins SA, Hanby AM, Holliday DL, Speirs V. Clinical and functional significance of loss of caveolin-1 expression in breast cancer-associated fibroblasts. J Pathol. 2012;227:490–8.

    Article  CAS  PubMed  Google Scholar 

  11. Di Vizio D, Morello M, Sotgia F, Pestell RG, Freeman MR, Lisanti MP. An absence of stromal caveolin-1 is associated with advanced prostate cancer, metastatic disease and epithelial Akt activation. Cell Cycle. 2009;8:2420–4.

    Article  PubMed  PubMed Central  Google Scholar 

  12. Jia Y, Wang N, Wang J, Tian H, Ma W, Wang K, et al. Down-regulation of stromal caveolin-1 expression in esophageal squamous cell carcinoma: a potent predictor of lymph node metastases, early tumor recurrence, and poor prognosis. Ann Surg Oncol. 2014;21:329–36.

    Article  PubMed  Google Scholar 

  13. Parmar MK, Torri V, Stewart L. Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. Stat Med. 1998;17:2815–34.

    Article  CAS  PubMed  Google Scholar 

  14. Williamson PR, Smith CT, Hutton JL, Marson AG. Aggregate data meta-analysis with time-to-event outcomes. Stat Med. 2002;21(e51):3337–51.

    Article  PubMed  Google Scholar 

  15. Tierney JF, Stewart LA, Ghersi D, Burdett S, Sydes MR. Practical methods for incorporating summary time-to-event data intometa-analysis. Trials. 2007;8:16.

    Article  PubMed  PubMed Central  Google Scholar 

  16. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ. 2003;327:557–60.

    Article  PubMed  PubMed Central  Google Scholar 

  17. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7:177–88.

    Article  CAS  PubMed  Google Scholar 

  18. Begg CB, Mazumdar M. Operating characteristics of a rank correlation test for publication bias. Biometrics. 1994;50:1088–101.

    Article  CAS  PubMed  Google Scholar 

  19. Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997;315:629–34.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  20. Witkiewicz AK, Dasgupta A, Nguyen KH, Liu C, Kovatich AJ, Schwartz GF, et al. Stromal caveolin-1 levels predict early DCIS progression to invasive breast cancer. Cancer Bio Ther. 2009;8:1071–9.

    Article  CAS  Google Scholar 

  21. El-Gendi SM, Mostafa MF, El-Gendi AM. Stromal caveolin-1 expression in breast carcinoma. Correlation with early tumor recurrence and clinical outcome. Pathol Oncol Res. 2012;18:459–69.

    Article  CAS  PubMed  Google Scholar 

  22. Witkiewicz AK, Dasgupta A, Sotgia F, Mercier I, Pestell RG, Sabel M, et al. An absence of stromal caveolin-1 expression predicts early tumor recurrence and poor clinical outcome in human breast cancers. Am J Pathol. 2009;174:2023–34.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  23. Sloan EK, Ciocca DR, Pouliot N, Natoli A, Restall C, Henderson MA, et al. Stromal cell expression of caveolin-1 predicts outcome in breast cancer. Am J Pathol. 2009;174:2035–43.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  24. Koo JS, Park S, Kim SI, Lee S, Park BW. The impact of caveolin protein expression in tumor stroma on prognosis of breast cancer. Tumour Biol. 2011;32:787–99.

    Article  CAS  PubMed  Google Scholar 

  25. Witkiewicz AK, Whitaker-Menezes D, Dasgupta A, Philp NJ, Lin Z, Gandra R, et al. Using the “reverse Warburg effect” to identify high-risk breast cancer patients: stromal MCT4 predicts poor clinical outcome in triple-negative breast cancers. Cell Cycle. 2012;11:1108–17.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  26. Ren M, Liu F, Zhu Y, Li Y, Lang R, Fan Y, et al. Absence of caveolin-1 expression in carcinoma-associated fibroblasts of invasive micropapillary carcinoma of the breast predicts poor patient outcome. Vichows Arch. 2014;465:291–8.

    Article  CAS  Google Scholar 

  27. Simpkins SA, Hanby AM, Holliday DL, Speirs V. Clinical and functional significance of loss of caveolin-1 expression in breast cancer-associated fibroblasts. J Pathol. 2012;227:290–8.

    Article  Google Scholar 

  28. Shan-Wei W, Kan-Lun X, Shu-Qin R, Li-Li Z, Li-Rong C. Overexpression of caveolin-1 in cancer-associated fibroblasts predicts good outcome in breast cancer. Breast Care (Basel). 2012;7:477–83.

    Article  Google Scholar 

  29. Qian N, Ueno T, Kawaguchi-Sakita N, Kawashima M, Yoshida N, Mikami Y, et al. Prognostic significance of tumor⁄stromal caveolin-1 expression in breast cancer patients. Cancer Sci. 2011;102:1590–6.

    Article  CAS  PubMed  Google Scholar 

  30. Ma X, Lei L, Nie W, Li Y, Zhang B, Zhang J, et al. Prognostic role of caveolin in breast cancer: a meta-analysis. Breast. 2013;22:462–9.

    Article  PubMed  Google Scholar 

  31. Ayala G, Morello M, Frolov A, You S, Li R, Rosati F, et al. Loss of caveolin-1 in prostate cancer stroma correlates with reduced relapse-free survival and is functionally relevant to tumour progression. J Pathol. 2013;231:77–87.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  32. Martinez-Outschoorn UE, Pavlides S, Whitaker-Menezes D, Daumer KM, Milliman JN, Chiavarina B, et al. Tumor cells induce the cancer associated fibroblast phenotype via caveolin-1 degradation: implications for breast cancer and DCIS therapy with autophagy inhibitors. Cell Cycle. 2010;9:2423–33.

    Article  CAS  PubMed  Google Scholar 

  33. Hayes DF, Isaacs C, Stearns V. Prognostic factors in breast cancer: current and new predictors of metastasis. J Mammary Gland Biol Neoplasia. 2001;6(e92):375.

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgements

The authors gratefully acknowledge the Personnel Training Project of Kunming University of Science and Technology, Kunming, China (No. KKSY201460047).

Author information

Authors and Affiliations

  1. Medical Faculty, Kunming University of Science and Technology, 650093, Kunming, Yunnan, China

    Xiuying Li

  2. LaoBoYunTang Medicine Co., Ltd, Chuxiong, China

    Jinfan Sun

  3. Department of Gynecology and Obstetrics, the First Affiliated Hospital of Kunming Medical University, Kunming, China

    Shuenqin Hu

Authors
  1. Xiuying Li
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Jinfan Sun
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Shuenqin Hu
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Xiuying Li.

Ethics declarations

Conflict of interest

X. Li, J. Sun and S. Hu declare that they have no competing interests.

Caption Electronic Supplementary Material

Supplementary Figure S1. Sensitivity analysis for OS, the expression of caveolin-1 in the tumor stroma

508_2017_1173_MOESM2_ESM.tif

Supplementary Figure S2. Sensitivity analysis for disease-free/progression-free survival (DFS/PFS), the expression of caveolin-1 in the tumor stroma

Supplementary Figure S3. Sensitivity analysis for OS, the expression of caveolin-1 in the cancer-associated fibroblasts

508_2017_1173_MOESM4_ESM.tif

Supplementary Figure S4. Sensitivity analysis for disease-free/progression-free survival (DFS/PFS), the expression of caveolin-1 in the cancer-associated fibroblasts

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Li, X., Sun, J. & Hu, S. Expression of caveolin-1 in breast cancer stroma as a potential prognostic biomarker of survival and progression: a meta-analysis. Wien Klin Wochenschr 129, 558–563 (2017). https://doi.org/10.1007/s00508-017-1173-3

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00508-017-1173-3

Keywords

Search

Navigation